A recent study showed that a GPCR membrane receptor, CXCR7, could facilitate NSCLC resistant to gefitinib via reactivating ERK signaling (Becker et al., 2019), but the possible participation of receptor transactivation in molecular mechanism has not been extensively reported. The gene discussed is ACKR3; the disease is non-small cell lung carcinoma.